BRISBANE, Calif. / Feb 28, 2024 / Business Wire / CareDx, Inc. (Nasdaq: CDNA) today reported financial results for the fourth quarter and full year ended December 31, 2023.
Fourth Quarter and Full Year 2023 Highlights
“In 2023, we met our challenges head-on as we navigated the impact of Medicare coverage changes. We reset our operations, strategically reduced our cost structure, and created a growth pathway for the company in the second half of the year, as we continued to focus on care for transplant patients,” said Alex Johnson, President of Patient and Testing Services, and a member of the Office of the CEO at CareDx. “Looking forward to 2024, we are focused on delivering high-value clinical and digital solutions to improve allograft survival, while generating evidence for expanding payer coverage and accelerating our path back to profitability.”
Q4 2023 Financial Results
Revenue for the three months ended December 31, 2023, was $65.6 million, a decrease of 20% compared with $82.4 million for the fourth quarter of 2022. Testing Services revenue for the fourth quarter 2023 was $46.7 million, a decrease of 29% compared with $65.4 million in the same period in 2022. Testing Services revenue was negatively impacted due to the Medicare Billing Article changes.
Total AlloSure and AlloMap patient results provided in the fourth quarter 2023 were approximately 39,900, a decrease of 16% as compared to the same quarter a year ago, and an increase of 4% compared to the third quarter of 2023. Patient and Digital Solutions revenue for the fourth quarter 2023 was $9.6 million, compared to $8.4 million in the same period in 2022, an increase of 14%. Product revenue for the fourth quarter 2023 was $9.2 million, compared to $8.6 million in the same period in 2022, an increase of 8%.
For the fourth quarter of 2023, net loss was $118.1 million, including $96.3 million accrual associated with damages related to alleged infringement of patent ‘544, compared to a net loss of $18.3 million in the fourth quarter of 2022. Basic and diluted net loss per share in the fourth quarter of 2023 was $2.21, compared to basic and diluted net loss per share of $0.34 in the fourth quarter of 2022.
Non-GAAP net loss was $9.3 million in the fourth quarter of 2023, compared to a non-GAAP net loss of $3.7 million in the fourth quarter of 2022. Basic and diluted non-GAAP net loss per share was $0.17 in the fourth quarter of 2023, compared to a basic and diluted non-GAAP net loss per share of $0.07 in the fourth quarter of 2022.
Adjusted EBITDA for the fourth quarter of 2023 was a loss of $10.3 million, compared to an adjusted EBITDA loss of $3.7 million in the fourth quarter of 2022.
Full Year 2023 Financial Results
Total revenue for the full year ended December 31, 2023, was $280.3 million, a decrease of 13% compared with $321.8 million in 2022. Testing Services revenue for the full year 2023 was $209.7 million, compared with $263.7 million in 2022, a decrease of 20%. Patient and Digital Solutions revenue for the full year 2023 was $37.1 million, compared to $28.8 million in 2022, an increase of 29%. Product revenue for the full year 2023 was $33.5 million, compared to $29.3 million in 2022, an increase of 15%.
Net loss for the full year 2023 was $190.3 million, including $96.3 million accrual associated with damages related to alleged infringement of patent ‘544, compared to a net loss of $76.6 million in 2022. Basic and diluted net loss per share for the full year 2023 was $3.54, compared to basic and diluted net loss per share of $1.44 in the full year 2022.
Non-GAAP net loss was $34.5 million for the full year 2023, compared to a non-GAAP net loss of $20.9 million for the full year ended 2022. Basic and diluted non-GAAP net loss per share was $0.64 in the full year of 2023, compared to a basic and diluted non-GAAP net loss per share of $0.39 in the full year of 2022.
Adjusted EBITDA for the full year of 2023 was a loss of $38.0 million, compared to an adjusted EBITDA loss of $17.5 million for the full year of 2022.
Cash and cash equivalents and marketable securities were $235.4 million as of December 31, 2023. Reduced cash used in operations from $25.2 million in 2022 to $18.4 million in 2023.
For additional information regarding non-GAAP financial measures discussed herein, please see “Use of Non-GAAP Financial Measures,” “Reconciliation of GAAP to Non-GAAP Financial Measures,” “Reconciliation of GAAP to Non-GAAP Gross Profit and Gross Margin,” and “Reconciliation of Non-GAAP to Adjusted EBITDA Financial Measures” below.
2024 Guidance
For the full year 2024, CareDx expects revenue to be in the range of $260 million to $274 million.
About CareDx – The Transplant Company
CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.
Forward-Looking Statements
This press release includes forward-looking statements, including expectations regarding CareDx’s 2024 revenue, CareDx’s plans to seek judicial review of jury decision and historical monetary damages on patent ‘544, CareDx’s focus in 2024 and CareDx’s proposed path to profitability. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, all of which are difficult to predict and many of which are beyond our control, including general economic and market factors, and global economic and marketplace uncertainties related to the COVID-19 pandemic, among others discussed in CareDx’s filings with the Securities and Exchange Commission (the “SEC”), including, but not limited to, the Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed by CareDx with the SEC on February 28, 2024, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx’s actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx’s forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
Use of Non-GAAP Financial Measures
CareDx has presented in this release certain financial information in accordance with U.S. Generally Accepted Accounting Principles (GAAP) and also on a non-GAAP basis, including non-GAAP cost of testing services, non-GAAP cost of product, non-GAAP cost of patient and digital solutions, non-GAAP research and development expenses, non-GAAP sales and marketing expenses, non-GAAP general and administrative expenses, non-GAAP other income, net, non-GAAP income tax expense, non-GAAP gross profit, non-GAAP gross margin (%), non-GAAP net loss, non-GAAP basic and diluted net loss per share, adjusted EBITDA, and non-GAAP operating expenses.
We define non-GAAP net loss and per share results as the GAAP net loss and per share results excluding the impacts of stock-based compensation; changes in estimated fair value of contingent consideration; acquisition-related impairment charges and amortization of purchased intangible assets and related tax effects; costs involved with completing an acquisition; unrealized loss on investments; realized gain on investments; restructuring charges and certain other charges. We define adjusted EBITDA as non-GAAP net loss before net interest income, income tax expense, depreciation and other (income) expense, net.
We are presenting these non-GAAP financial measures to assist investors in assessing our operating results through the eyes of management and because we believe that these measures provide an additional tool for investors to use in comparing our core business operating results over multiple periods. Management believes this non-GAAP information is useful for investors, when considered in conjunction with CareDx’s GAAP financial statements, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of CareDx’s operating results as reported under GAAP. These non-GAAP financial measures should not be considered in isolation from, or as a substitute for, financial information prepared in accordance with GAAP. These non-GAAP financial measures are not necessarily comparable to similarly titled measures presented by other companies. A reconciliation between GAAP and non-GAAP financial information is provided immediately following the financial tables.
CareDx, Inc. Consolidated Statements of Operations (Unaudited) (In thousands, except share and per share data) | |||||||||||||||
| Three Months Ended December 31, |
| Twelve Months Ended December 31, | ||||||||||||
| 2023 |
| 2022 |
| 2023 |
| 2022 | ||||||||
Revenue: |
|
|
|
|
|
|
| ||||||||
Testing services revenue | $ | 46,703 |
|
| $ | 65,418 |
|
| $ | 209,685 |
|
| $ | 263,748 |
|
Product revenue |
| 9,244 |
|
|
| 8,555 |
|
|
| 33,517 |
|
|
| 29,251 |
|
Patient and digital solutions |
| 9,622 |
|
|
| 8,411 |
|
|
| 37,122 |
|
|
| 28,794 |
|
Total revenue |
| 65,569 |
|
|
| 82,384 |
|
|
| 280,324 |
|
|
| 321,793 |
|
Operating expenses: |
|
|
|
|
|
|
| ||||||||
Cost of testing services |
| 13,805 |
|
|
| 18,657 |
|
|
| 57,642 |
|
|
| 72,286 |
|
Cost of product |
| 5,637 |
|
|
| 4,617 |
|
|
| 18,379 |
|
|
| 17,639 |
|
Cost of patient and digital solutions |
| 6,171 |
|
|
| 6,216 |
|
|
| 25,978 |
|
|
| 22,287 |
|
Research and development |
| 18,276 |
|
|
| 23,570 |
|
|
| 81,866 |
|
|
| 90,388 |
|
Sales and marketing |
| 19,999 |
|
|
| 23,668 |
|
|
| 83,334 |
|
|
| 96,027 |
|
General and administrative |
| 26,541 |
|
|
| 24,776 |
|
|
| 117,868 |
|
|
| 100,397 |
|
Restructuring costs |
| 1,472 |
|
|
| — |
|
|
| 2,320 |
|
|
| — |
|
Litigation expense |
| 96,300 |
|
|
| — |
|
|
| 96,300 |
|
|
| — |
|
Total operating expenses |
| 188,201 |
|
|
| 101,504 |
|
|
| 483,687 |
|
|
| 399,024 |
|
Loss from operations |
| (122,632 | ) |
|
| (19,120 | ) |
|
| (203,363 | ) |
|
| (77,231 | ) |
Other income (expense): |
|
|
|
|
|
|
| ||||||||
Interest income, net |
| 3,159 |
|
|
| 1,870 |
|
|
| 11,867 |
|
|
| 3,762 |
|
Change in estimated fair value of common stock warrant liability |
| — |
|
|
| 18 |
|
|
| 10 |
|
|
| 107 |
|
Other income (expense), net |
| 1,541 |
|
|
| (924 | ) |
|
| 1,343 |
|
|
| (2,872 | ) |
Total other income |
| 4,700 |
|
|
| 964 |
|
|
| 13,220 |
|
|
| 997 |
|
Loss before income taxes |
| (117,932 | ) |
|
| (18,156 | ) |
|
| (190,143 | ) |
|
| (76,234 | ) |
Income tax expense |
| (165 | ) |
|
| (173 | ) |
|
| (141 | ) |
|
| (379 | ) |
Net loss | $ | (118,097 | ) |
| $ | (18,329 | ) |
| $ | (190,284 | ) |
| $ | (76,613 | ) |
Net loss per share: |
|
|
|
|
|
|
| ||||||||
Basic | $ | (2.21 | ) |
| $ | (0.34 | ) |
| $ | (3.54 | ) |
| $ | (1.44 | ) |
Diluted | $ | (2.21 | ) |
| $ | (0.34 | ) |
| $ | (3.54 | ) |
| $ | (1.44 | ) |
Weighted-average shares used to compute net loss per share: |
|
|
|
|
|
|
| ||||||||
Basic |
| 53,388,830 |
|
|
| 53,524,637 |
|
|
| 53,764,705 |
|
|
| 53,321,625 |
|
Diluted |
| 53,388,830 |
|
|
| 53,524,637 |
|
|
| 53,764,705 |
|
|
| 53,321,625 |
|
CareDx, Inc. Consolidated Balance Sheets (In thousands) | |||||||
| As of December 31, | ||||||
| 2023 |
| 2022 | ||||
Assets |
|
|
| ||||
Current assets: |
|
|
| ||||
Cash and cash equivalents | $ | 82,197 |
|
| $ | 89,921 |
|
Marketable securities |
| 153,221 |
|
|
| 203,168 |
|
Accounts receivable |
| 51,061 |
|
|
| 66,312 |
|
Inventory |
| 19,471 |
|
|
| 19,232 |
|
Prepaid and other current assets |
| 7,763 |
|
|
| 9,216 |
|
Total current assets |
| 313,713 |
|
|
| 387,849 |
|
Property and equipment, net |
| 35,246 |
|
|
| 35,529 |
|
Operating leases right-of-use assets |
| 29,891 |
|
|
| 34,689 |
|
Intangible assets, net |
| 45,701 |
|
|
| 43,051 |
|
Goodwill |
| 40,336 |
|
|
| 37,523 |
|
Restricted cash |
| 586 |
|
|
| 522 |
|
Other assets |
| 1,353 |
|
|
| 3,828 |
|
Total assets | $ | 466,826 |
|
| $ | 542,991 |
|
Liabilities and stockholders’ equity |
|
|
| ||||
Current liabilities: |
|
|
| ||||
Accounts payable | $ | 12,872 |
|
| $ | 9,942 |
|
Accrued compensation |
| 19,703 |
|
|
| 16,902 |
|
Accrued and other liabilities |
| 45,497 |
|
|
| 49,131 |
|
Total current liabilities |
| 78,072 |
|
|
| 75,975 |
|
Deferred tax liability |
| 136 |
|
|
| — |
|
Common stock warrant liability |
| — |
|
|
| 32 |
|
Deferred payments for intangible assets |
| 2,461 |
|
|
| 2,418 |
|
Operating lease liability, less current portion |
| 28,278 |
|
|
| 33,406 |
|
Other liabilities |
| 96,551 |
|
|
| 249 |
|
Total liabilities |
| 205,498 |
|
|
| 112,080 |
|
Commitments and contingencies |
|
|
| ||||
Stockholders’ equity: |
|
|
| ||||
Common stock |
| 49 |
|
|
| 52 |
|
Additional paid-in capital |
| 946,511 |
|
|
| 898,806 |
|
Accumulated other comprehensive loss |
| (6,963 | ) |
|
| (7,503 | ) |
Accumulated deficit |
| (678,269 | ) |
|
| (460,444 | ) |
Total stockholders’ equity |
| 261,328 |
|
|
| 430,911 |
|
Total liabilities and stockholders’ equity | $ | 466,826 |
|
| $ | 542,991 |
|
CareDx, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) (In thousands) | |||||||||||||||
| Three Months Ended December 31, |
| Twelve Months Ended December 31, | ||||||||||||
| 2023 |
| 2022 |
| 2023 |
| 2022 | ||||||||
Cost of testing services reconciliation: |
|
|
|
|
|
|
| ||||||||
GAAP cost of testing services | $ | 13,805 |
|
| $ | 18,657 |
|
| $ | 57,642 |
|
| $ | 72,286 |
|
Stock-based compensation expense |
| (387 | ) |
|
| (474 | ) |
|
| (1,854 | ) |
|
| (1,529 | ) |
Acquisition related-amortization of purchased intangibles |
| (329 | ) |
|
| (329 | ) |
|
| (1,316 | ) |
|
| (1,316 | ) |
Non-GAAP cost of testing services | $ | 13,089 |
|
| $ | 17,854 |
|
| $ | 54,472 |
|
| $ | 69,441 |
|
Cost of product reconciliation: |
|
|
|
|
|
|
| ||||||||
GAAP cost of product | $ | 5,750 |
|
| $ | 4,617 |
|
| $ | 18,492 |
|
| $ | 17,639 |
|
Stock-based compensation expense |
| (230 | ) |
|
| (269 | ) |
|
| (1,165 | ) |
|
| (1,120 | ) |
Acquisition related-amortization of purchased intangibles |
| (413 | ) |
|
| (411 | ) |
|
| (1,655 | ) |
|
| (1,716 | ) |
Restructuring costs |
| (113 | ) |
|
| — |
|
|
| (113 | ) |
|
| — |
|
Non-GAAP cost of product | $ | 4,994 |
|
| $ | 3,937 |
|
| $ | 15,559 |
|
| $ | 14,803 |
|
Cost of patient and digital solutions reconciliation: |
|
|
|
|
|
|
| ||||||||
GAAP cost of patient and digital solutions | $ | 6,226 |
|
| $ | 6,216 |
|
| $ | 26,047 |
|
| $ | 22,287 |
|
Stock-based compensation expense |
| (311 | ) |
|
| (449 | ) |
|
| (1,377 | ) |
|
| (1,331 | ) |
Acquisition related-amortization of purchased intangibles |
| (271 | ) |
|
| (236 | ) |
|
| (1,039 | ) |
|
| (945 | ) |
Restructuring costs |
| (55 | ) |
|
| — |
|
|
| (69 | ) |
|
| — |
|
Non-GAAP cost of patient and digital solutions | $ | 5,589 |
|
| $ | 5,531 |
|
| $ | 23,562 |
|
| $ | 20,011 |
|
Research and development expenses reconciliation: |
|
|
|
|
|
|
| ||||||||
GAAP research and development expenses | $ | 18,617 |
|
| $ | 23,570 |
|
| $ | 82,452 |
|
| $ | 90,388 |
|
Stock-based compensation expense |
| (1,399 | ) |
|
| (820 | ) |
|
| (6,556 | ) |
|
| (7,391 | ) |
Asset impairments and write-downs |
| — |
|
|
| — |
|
|
| — |
|
|
| (340 | ) |
Restructuring costs |
| (341 | ) |
|
| — |
|
|
| (586 | ) |
|
| — |
|
Non-GAAP research and development expenses | $ | 16,877 |
|
| $ | 22,750 |
|
| $ | 75,310 |
|
| $ | 82,657 |
|
Sales and marketing expenses reconciliation: |
|
|
|
|
|
|
| ||||||||
GAAP sales and marketing expenses | $ | 20,254 |
|
| $ | 23,668 |
|
| $ | 84,137 |
|
| $ | 96,027 |
|
Stock-based compensation expense |
| (2,913 | ) |
|
| (4,701 | ) |
|
| (12,470 | ) |
|
| (14,403 | ) |
Acquisition related-amortization of purchased intangibles |
| (641 | ) |
|
| (550 | ) |
|
| (2,457 | ) |
|
| (2,252 | ) |
Restructuring costs |
| (255 | ) |
|
| — |
|
|
| (803 | ) |
|
| — |
|
Non-GAAP sales and marketing expenses | $ | 16,445 |
|
| $ | 18,417 |
|
| $ | 68,407 |
|
| $ | 79,372 |
|
General and administrative expenses reconciliation: |
|
|
|
|
|
|
| ||||||||
GAAP general and administrative expenses | $ | 123,549 |
|
| $ | 24,776 |
|
| $ | 214,917 |
|
| $ | 100,397 |
|
Stock-based compensation expense |
| (4,720 | ) |
|
| (5,413 | ) |
|
| (25,664 | ) |
|
| (20,779 | ) |
Change in estimated fair value of contingent consideration |
| (946 | ) |
|
| 103 |
|
|
| (2,677 | ) |
|
| (727 | ) |
Acquisition related fees and expenses |
| (51 | ) |
|
| (212 | ) |
|
| (589 | ) |
|
| (599 | ) |
Restructuring costs |
| (708 | ) |
|
| — |
|
|
| (749 | ) |
|
| — |
|
Litigation expense |
| (96,300 | ) |
|
| — |
|
|
| (96,300 | ) |
|
| — |
|
Other charges |
| — |
|
|
| — |
|
|
| (64 | ) |
|
| — |
|
Non-GAAP general and administrative expenses | $ | 20,824 |
|
| $ | 19,254 |
|
| $ | 88,874 |
|
| $ | 78,292 |
|
Total other (expense) income reconciliation: |
|
|
|
|
|
|
| ||||||||
GAAP other expense, net | $ | 4,700 |
|
| $ | 964 |
|
| $ | 13,220 |
|
| $ | 997 |
|
Unrealized loss on investments |
| — |
|
|
| 965 |
|
|
| 1,190 |
|
|
| 1,181 |
|
Realized gain on investment |
| (1,468 | ) |
|
| — |
|
|
| (1,468 | ) |
|
| — |
|
Investment impairment |
| — |
|
|
| — |
|
|
| 1,000 |
|
|
| 500 |
|
Other charges (income) |
| — |
|
|
| 11 |
|
|
| (2,081 | ) |
|
| 43 |
|
Non-GAAP other income, net | $ | 3,232 |
|
| $ | 1,940 |
|
| $ | 11,861 |
|
| $ | 2,721 |
|
Income tax expense reconciliation: |
|
|
|
|
|
|
| ||||||||
GAAP income tax expense | $ | (165 | ) |
| $ | (173 | ) |
| $ | (141 | ) |
| $ | (379 | ) |
Tax effect related to amortization of purchased intangibles |
| (99 | ) |
|
| (98 | ) |
|
| (398 | ) |
|
| (419 | ) |
Non-GAAP income tax expense | $ | (264 | ) |
| $ | (271 | ) |
| $ | (539 | ) |
| $ | (798 | ) |
CareDx, Inc. GAAP and Non-GAAP Operating Expenses (Unaudited) (In thousands) | |||||||||||||||
| Three Months Ended December 31, |
| Twelve Months Ended December 31, | ||||||||||||
| 2023 |
| 2022 |
| 2023 |
| 2022 | ||||||||
GAAP operating expenses: |
|
|
|
|
|
|
| ||||||||
Research and development | $ | 18,617 |
| $ | 23,570 |
| $ | 82,452 |
| $ | 90,388 | ||||
Sales and marketing |
| 20,254 |
|
|
| 23,668 |
|
|
| 84,137 |
|
|
| 96,027 |
|
General and administrative |
| 123,549 |
|
|
| 24,776 |
|
|
| 214,917 |
|
|
| 100,397 |
|
Total GAAP operating expenses | $ | 162,420 |
|
| $ | 72,014 |
|
| $ | 381,506 |
|
| $ | 286,812 |
|
|
|
|
|
|
|
|
| ||||||||
Non-GAAP operating expenses: |
|
|
|
|
|
|
| ||||||||
Research and development | $ | 16,877 |
|
| $ | 22,750 |
|
| $ | 75,310 |
|
| $ | 82,657 |
|
Sales and marketing |
| 16,445 |
|
|
| 18,417 |
|
|
| 68,407 |
|
|
| 79,372 |
|
General and administrative |
| 20,824 |
|
|
| 19,254 |
|
|
| 88,874 |
|
|
| 78,292 |
|
Total Non-GAAP operating expenses | $ | 54,146 |
|
| $ | 60,421 |
|
| $ | 232,591 |
|
| $ | 240,321 |
|
CareDx, Inc. Reconciliation of GAAP to Non-GAAP Gross Profit and Gross Margin (Unaudited) (In thousands, except percentages) | |||||||||||||||
| Three Months Ended December 31, |
| Twelve Months Ended December 31, | ||||||||||||
| 2023 |
| 2022 |
| 2023 |
| 2022 | ||||||||
Total revenue | $ | 65,569 |
|
| $ | 82,384 |
|
| $ | 280,324 |
|
| $ | 321,793 |
|
GAAP cost of sales |
| 25,781 |
|
|
| 29,490 |
|
|
| 102,181 |
|
|
| 112,212 |
|
GAAP gross profit |
| 39,788 |
|
|
| 52,894 |
|
|
| 178,143 |
|
|
| 209,581 |
|
Stock-based compensation expense |
| 928 |
|
|
| 1,192 |
|
|
| 4,396 |
|
|
| 3,980 |
|
Restructuring costs |
| 168 |
|
|
| — |
|
|
| 182 |
|
|
| — |
|
Acquisition related-amortization of purchased intangibles |
| 1,013 |
|
|
| 976 |
|
|
| 4,010 |
|
|
| 3,977 |
|
Non-GAAP gross profit | $ | 41,897 |
|
| $ | 55,062 |
|
| $ | 186,731 |
|
| $ | 217,538 |
|
Non-GAAP gross margin % |
| 64 | % |
|
| 67 | % |
|
| 67 | % |
|
| 68 | % |
CareDx, Inc. Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) (In thousands, except share and per share data) | |||||||||||||||
| Three Months Ended December 31, |
| Twelve Months Ended December 31, | ||||||||||||
| 2023 |
| 2022 |
| 2023 |
| 2022 | ||||||||
GAAP net loss | $ | (118,097 | ) |
| $ | (18,329 | ) |
| $ | (190,284 | ) |
| $ | (76,613 | ) |
Stock-based compensation expense |
| 9,960 |
|
|
| 12,126 |
|
|
| 49,086 |
|
|
| 46,553 |
|
Unrealized loss on investments |
| — |
|
|
| 965 |
|
|
| 1,190 |
|
|
| 1,181 |
|
Realized gain on investments |
| (1,468 | ) |
|
| — |
|
|
| (1,468 | ) |
|
| — |
|
Acquisition related-amortization of purchased intangibles |
| 1,654 |
|
|
| 1,526 |
|
|
| 6,467 |
|
|
| 6,229 |
|
Acquisition related fees and expenses |
| 51 |
|
|
| 212 |
|
|
| 589 |
|
|
| 599 |
|
Change in estimated fair value of contingent consideration |
| 946 |
|
|
| (103 | ) |
|
| 2,677 |
|
|
| 727 |
|
Tax effect related to amortization of purchased intangibles |
| (99 | ) |
|
| (98 | ) |
|
| (398 | ) |
|
| (419 | ) |
Asset impairments and write-downs |
| — |
|
|
| — |
|
|
| 1,000 |
|
|
| 840 |
|
Litigation expense |
| 96,300 |
|
|
| — |
|
|
| 96,300 |
|
|
| — |
|
Restructuring costs |
| 1,472 |
|
|
| — |
|
|
| 2,320 |
|
|
| — |
|
Other charges |
| — |
|
|
| 11 |
|
|
| (2,017 | ) |
|
| 43 |
|
Non-GAAP net loss | $ | (9,281 | ) |
| $ | (3,690 | ) |
| $ | (34,538 | ) |
| $ | (20,860 | ) |
|
|
|
|
|
|
|
| ||||||||
GAAP basic and diluted net loss per share | $ | (2.21 | ) |
| $ | (0.34 | ) |
| $ | (3.54 | ) |
| $ | (1.44 | ) |
|
|
|
|
|
|
|
| ||||||||
Non-GAAP basic net loss per share | $ | (0.17 | ) |
| $ | (0.07 | ) |
| $ | (0.64 | ) |
| $ | (0.39 | ) |
Non-GAAP diluted net loss per share | $ | (0.17 | ) |
| $ | (0.07 | ) |
| $ | (0.64 | ) |
| $ | (0.39 | ) |
|
|
|
|
|
|
|
| ||||||||
Shares used in computing non-GAAP basic net loss per share |
| 53,388,830 |
|
|
| 53,524,637 |
|
|
| 53,764,705 |
|
|
| 53,321,625 |
|
Shares used in computing non-GAAP diluted net loss per share |
| 53,388,830 |
|
|
| 53,524,637 |
|
|
| 53,764,705 |
|
|
| 53,321,625 |
|
CareDx, Inc. Reconciliation of Non-GAAP to Adjusted EBITDA Financial Measures (Unaudited) (In thousands) | |||||||||||||||
| Three Months Ended December 31, |
| Twelve Months Ended December 31, | ||||||||||||
| 2023 |
| 2022 |
| 2023 |
| 2022 | ||||||||
Non-GAAP net loss | $ | (9,281 | ) |
| $ | (3,690 | ) |
| $ | (34,538 | ) |
| $ | (20,860 | ) |
Interest income |
| (3,159 | ) |
|
| (1,870 | ) |
|
| (11,867 | ) |
|
| (3,762 | ) |
Income tax expense |
| 264 |
|
|
| 272 |
|
|
| 539 |
|
|
| 798 |
|
Depreciation expense |
| 1,978 |
|
|
| 1,682 |
|
|
| 7,882 |
|
|
| 5,248 |
|
Other (income) expense, net |
| (72 | ) |
|
| (70 | ) |
|
| 7 |
|
|
| 1,041 |
|
Adjusted EBITDA | $ | (10,270 | ) |
| $ | (3,676 | ) |
| $ | (37,977 | ) |
| $ | (17,535 | ) |
| Last Trade: | US$21.18 |
| Daily Change: | 0.09 0.43 |
| Daily Volume: | 247,295 |
| Market Cap: | US$1.140B |
December 11, 2024 November 04, 2024 October 23, 2024 October 21, 2024 October 15, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
